Abstract
Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Current Vascular Pharmacology
Title:Acute Coronary Syndromes in Patients with Chronic Kidney Disease
Volume: 11 Issue: 5
Author(s): Beata Franczyk-Skóra, Anna Gluba, Maciej Banach, Piotr Rozentryt, Lech Poloński and Jacek Rysz
Affiliation:
Keywords: Acute coronary syndrome, chronic kidney disease, coronary interventions, treatment.
Abstract: Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Export Options
About this article
Cite this article as:
Franczyk-Skóra Beata, Gluba Anna, Banach Maciej, Rozentryt Piotr, Poloński Lech and Rysz Jacek, Acute Coronary Syndromes in Patients with Chronic Kidney Disease, Current Vascular Pharmacology 2013; 11 (5) . https://dx.doi.org/10.2174/1570161111311050013
DOI https://dx.doi.org/10.2174/1570161111311050013 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews Analysis of Chinese Herbal Formulae Recommended for COVID-19 in Different Schemes in China: A Data Mining Approach
Combinatorial Chemistry & High Throughput Screening Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Role of Exosomes in Breast Cancer Management: Evidence-Based Review
Current Cancer Drug Targets Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Effects of Hyperlipidemia and Cardiovascular Diseases on Proliferation, Differentiation and Homing of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Immune Endocrinological Evaluation in Patients with Severe Vascular Acquired Brain Injuries: Therapeutical Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Role for Poly(ADP-ribose) Polymerase Activation in Diabetic Nephropathy, Neuropathy and Retinopathy
Current Vascular Pharmacology Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry Gene Therapy Strategies Towards Immune Tolerance to Treat the Autoimmune Diseases
Current Gene Therapy Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update
Coronaviruses Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity
Current Topics in Medicinal Chemistry Initiation of Dialysis: A Mini-Review of a Changing Paradigm
Cardiovascular & Hematological Disorders-Drug Targets The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design